Sanofi Reports final analysis Data for Evolocumab in Hepatitis C

Sanofi today announced final analysis results for Evolocumab in patients with Hepatitis C. The study demonstrated that Evolocumab demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Hepatitis C and support the continued development of Evolocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Evolocumab was consistent with previous observations, with no new safety signals identified.